Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00582_DB01211_nanopub.RAXXv2Fk2r1wDH9rd5tdR8efdu2SIZT-OISE5KuF-k4k0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00582_DB01211 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00582_DB01211 label "DDI between Voriconazole and Clarithromycin - Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of clarithromycin by decreasing its metabolism. Clarithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. [drugbank_resource:DB00582_DB01211]" assertion.
- drugbank_resource:DB00582_DB01211 identifier "drugbank_resource:DB00582_DB01211" assertion.
- drugbank_resource:DB00582_DB01211 title "DDI between Voriconazole and Clarithromycin - Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of clarithromycin by decreasing its metabolism. Clarithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed." assertion.
- drugbank:DB00582 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00582_DB01211 assertion.
- drugbank:DB01211 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00582_DB01211 assertion.